• Molecular NameCefdinir
  • SynonymCefdirnir; CFDN
  • Weight395.42
  • Drugbank_IDDB00535
  • ACS_NO91832-40-5
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)-0.08
  • pkaN/A
  • LogD (pH=7, predicted)-3.89
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)0.05
  • LogSw (predicted, AB/LogsW2.0)3.43
  • Sw (mg/ml) (predicted, ACD/Labs)0.63
  • No.of HBond Donors5
  • No.of HBond Acceptors10
  • No.of Rotatable Bonds5
  • TPSA211.75
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA semi-synthetic, broad-spectrum antibiotic in the third generation of the cephalosporin class, proven effective for common bacterial infections of the ear, sinus, throat, and skin.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability18.5
  • Protein binding65.0
  • Volume of distribution (VD)1.85 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmNegligible
  • Half life1.45 h
  • ExcretionRenal
  • Urinary Excretion13~23
  • Clerance13 ml/min/kg
  • ToxicityInformation on cefdinir overdosage in humans is not available. In acute rodent toxicity studies, a single oral 5600-mg/kg dose produced no adverse effects. Toxic signs and symptoms following overdosage with other b-lactam antibiotics have included nausea, vomiting, epigastric distress, diarrhea, and convulsions.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A